FDA Approves Expansion of Alpha Tau’s U.S. REGAIN Trial

An FDA-approved IDE supplement expands the REGAIN trial from 10 to 20 patients and adds study endpoints and an interim analysis. Trial data are scheduled for presentation at the SNO 2026 Annual Meeting.